Zoetis Inc. ZTS NYSE

Zoetis Inc. (ZTS) reported total assets of $15.47B and total liabilities of $12.14B for fiscal year 2025, resulting in total equity of $3.33B.

The company held $2.31B in cash and short-term investments. Total debt stood at $9.49B, with net debt of $7.18B. The Debt-to-Equity (D/E) ratio was 2.85 (leveraged).

Current ratio is 3.03, indicating strong short-term liquidity. Interest coverage is 14.8x (strong).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (76/100) — Total assets $15.47B and equity $3.33B support the company's competitive scale
• VALUE (48/100) — Debt-to-Equity 2.85 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 71/100 with 4/7 criteria passed.

REGN

Regeneron Pharmaceuticals, Inc.

$755.51

+1.21%

CI

Cigna Corporation

$272.60

-0.92%

ELV

Elevance Health Inc.

$313.35

-0.86%

COR

Cencora, Inc.

$319.90

+0.24%

BDX

Becton, Dickinson and Company

$155.73

+0.19%

TAK

Takeda Pharmaceutical Company Limited

$17.85

+0.17%

ARGX

argenx SE

$828.35

+2.36%

IDXX

IDEXX Laboratories, Inc.

$584.05

+1.75%